Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
13F holders, Q2 2022
Institutional positions in Xilio Therapeutics, Inc. as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 33
- −7 vs. Q1 2022
- Shares held
- 17.9M
- −893.2K (−4.8%) vs. Q1 2022
- Total value
- $52.2M
- −$80.5M (−60.7%) vs. Q1 2022
- New holders
- 8
- 5 more added
- Sold out
- 15
- 12 more reduced
1 institution that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting XLO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 27 | $32.6M |
| Q1 2026 | 24 | $22.0M |
| Q4 2025 | 37 | $25.4M |
| Q3 2025 | 36 | $18.6M |
| Q2 2025 | 35 | $16.2M |
| Q1 2025 | 35 | $16.3M |
| Q4 2024 | 35 | $24.7M |
| Q3 2024 | 33 | $12.6M |
| Q2 2024 | 32 | $13.7M |
| Q1 2024 | 31 | $13.5M |
| Q4 2023 | 34 | $9.03M |
| Q3 2023 | 31 | $33.5M |
| Q2 2023 | 32 | $41.9M |
| Q1 2023 | 32 | $51.0M |
| Q4 2022 | 28 | $42.8M |
| Q3 2022 | 29 | $48.3M |
| Q2 2022 | 33 | $52.2M |
| Q1 2022 | 41 | $132.7M |
| Q4 2021 | 42 | $303.1M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2022
Shares, value and share of portfolio for each institution holding Xilio Therapeutics, Inc.; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| New York State Common Retirement Fund | 64 | $0 | 0.00% | −5,568−98.9% | Reduced |
| Wells Fargo & Company | 51 | $0 | 0.00% | −1,612−96.9% | Reduced |
| Citigroup Inc | 67 | $0 | 0.00% | −256−79.3% | Reduced |
| Credit Suisse AG | 4 | $0 | 0.00% | +4 | New |
| JPMorgan Chase & Co | 2,735 | $8.00K | 0.00% | −2,109−43.5% | Reduced |
| UBS Group AG | 2,814 | $9.00K | 0.00% | +1,850+191.9% | Added |
| Cannell Capital LLC | 4,545 | $13.0K | 0.00% | +4,545 | New |
| Tower Research Capital LLC (TRC) | 6,155 | $18.0K | 0.00% | +1,861+43.3% | Added |
| Morgan Stanley | 7,040 | $20.0K | 0.00% | +4,936+234.6% | Added |
| RBF Capital, LLC | 10,072 | $29.0K | 0.00% | +10,072 | New |
| Northern Trust Corp | 12,900 | $38.0K | 0.00% | −50,673−79.7% | Reduced |
| State Street Corp | 15,690 | $46.0K | 0.00% | −78,171−83.3% | Reduced |
| Ergoteles LLC | 17,548 | $51.0K | 0.00% | +17,548 | New |
| Bailard, Inc. | 36,632 | $107.0K | 0.00% | +36,632 | New |
| BlackRock Inc. | 47,663 | $139.0K | 0.00% | −252,093−84.1% | Reduced |
| Millennium Management LLC | 49,956 | $146.0K | 0.00% | +49,956 | New |
| Renaissance Technologies LLC | 75,300 | $220.0K | 0.00% | +75,300 | New |
| Geode Capital Management, LLC | 83,589 | $244.0K | 0.00% | −58,121−41.0% | Reduced |
| Norges Bank | 121,887 | $355.9K | 0.00% | −278,113−69.5% | Reduced |
| Laurion Capital Management LP | 142,900 | $417.0K | 0.02% | +142,900 | New |
| FIL Ltd | 218,705 | $639.0K | 0.00% | 00.0% | Unchanged |
| Harvard Management Co Inc | 416,059 | $1.22M | 0.14% | 00.0% | Unchanged |
| Vanguard Group Inc | 419,165 | $1.22M | 0.00% | +2,772+0.7% | Added |
| Artal Group S.A. | 450,000 | $1.31M | 0.07% | 00.0% | Unchanged |
| Soleus Capital Management, L.P. | 453,660 | $1.32M | 0.21% | −23,835−5.0% | Reduced |
| AJU IB Investment Co., Ltd. | 667,742 | $1.95M | 3.78% | 00.0% | Unchanged |
| Rock Springs Capital Management LP | 1,362,878 | $3.98M | 0.12% | +171,784+14.4% | Added |
| RiverVest Venture Management LLC | 1,441,444 | $4.21M | 6.19% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 1,649,711 | $4.82M | 0.13% | −352,506−17.6% | Reduced |
| Deerfield Management Company, L.P. (Series C) | 2,078,692 | $6.07M | 0.13% | 00.0% | Unchanged |
| FMR LLC | 2,521,333 | $7.36M | 0.00% | −69,389−2.7% | Reduced |
| Atlas Venture Life Science Advisors, LLC | 2,759,344 | $8.06M | 1.35% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 2,805,413 | $8.19M | 0.96% | 00.0% | Unchanged |
| Monashee Investment Management LLC | 0 | $0 | 0.00% | −163,066−100.0% | Sold out |
| Bank of New York Mellon Corp | 0 | $0 | 0.00% | −21,029−100.0% | Sold out |
| Charles Schwab Investment Management Inc | 0 | $0 | 0.00% | −16,100−100.0% | Sold out |
| Nuveen Asset Management, LLC | 0 | $0 | 0.00% | −11,284−100.0% | Sold out |
| Granite Point Capital Management, L.P. | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Deutsche Bank AG | 0 | $0 | 0.00% | −4,026−100.0% | Sold out |
| American International Group, Inc. | 0 | $0 | 0.00% | −3,795−100.0% | Sold out |
| California State Teachers Retirement System | 0 | $0 | 0.00% | −3,208−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −2,611−100.0% | Sold out |
| STRS Ohio | 0 | $0 | 0.00% | −1,700−100.0% | Sold out |
| Barclays PLC | 0 | $0 | 0.00% | −1,243−100.0% | Sold out |
| Amalgamated Bank | 0 | $0 | 0.00% | −1,078−100.0% | Sold out |
| Legal & General Group Plc | 0 | $0 | 0.00% | −698−100.0% | Sold out |
| Ameritas Investment Partners, Inc. | 0 | $0 | 0.00% | −573−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −470−100.0% | Sold out |
| Amalgamated Financial Corp. | – | – | – | – | Not filed |